Company Overview and News
FOR STABLE SUPPLY President Duterte (center) joins officials of Aboitiz Power and TeaM Energy at the inauguration of the 420-megawatt Pagbilao 3 power plant in Quezon province on Thursday. Seated with Mr. Duterte are (front row, from left) Jera Co. Inc. Senior vice president Toshiro Kodama, Energy Secretary Alfonso Cusi, Aboitiz Power chair Erramon Aboitiz; and Marubeni Corp. senior executive officer Yasuo Hirota.
ABZPF ABZPY MARUF AP
PAGBILAO, Quezon — Aboitiz Power Corp. and TeaM Energy Corp. have formally launched on Thursday the 420-megawatt (MW) coal-fired power plant in Pagbilao, Quezon that is expected to boost electricity supply in Luzon.
ABZPF ABZPY AP
Last May 18, BusinessWorld, the most read and most respected business newspaper in the Philippines, triumphantly staged the third edition of its annual BusinessWorld Economic Forum in the Grand Ballroom of Grand Hyatt Manila, in Bonifacio Global City, Taguig City.
MER GTCAP GTCXY SVTMF SMCP1 ABZPY BDOUY SM BDOUF SMGBF SMIVY SMC PNX3B PNXP PNX3A MPCFF PNX UBNC MPCIY SMGBY ABZPF BDO SMC2B SMC2A SMC2D SMC2C MPI SMC2F SMC2E AP LTG
A unit of the Manila Electric Co. is now considering to look for a new contractor to build a planned 600-megawatt power plant at the Redondo Peninsula in Zambales as the previous contractor had proposed a new contract that would make the project nonviable.
ABZPF MER ABZPY AP
Last week, May 22, a BusinessWorld report said “DoE forecast for peak power demand exceeded on May 17” referring to 10,688 MW peak demand in the Luzon grid on May 17 reported by the National Grid Corp. of the Philippines (NGCP) vs peak demand in 2017 of 10,054 MW.
ABZPF NG ABZPY NGGTF NGG AP
ABOITIZ Power Corp. is targeting to increase its contracted capacity to contestable customers by at least 100 megawatts (MW) this year as it looks to target electricity users with consumption of at least 750 kilowatts, its president said.
ABZPF ABZPY AP
THE leadership transition at Aboitiz Equity Ventures, Inc. (AEV) is on course to be completed next year, with the holding firm establishing a committee composed of top management officials to guide the company’s board of directors.
ABZPF UBNC ABTZY ABZPY AEV AP
A REGIONAL expansion will be a big part of Aboitiz Power Corp.’s new 2025 targets when it holds a strategic planning this year, its president said on Monday, as the company is on track to meet its 2020 target capacity of 4,000 megawatts (MW).
ABZPF ABZPY AP
This was the message of Udenna Corp. founder, Chairman and Chief Executive Officer Dennis A. Uy in his keynote speech during the BusinessWorld Economic Forum 2018, titled: “Disruptor or Disrupted?” at the Grand Hyatt Manila in Taguig City on Friday last week.
ABZPF PNX UBNC PNX3B PNXP PNX3A ABZPY AP
THE TWIN FORCES of innovation and disruption are sweeping the country’s current business landscape, and industry leaders must be quick to adapt or be left behind.
ABZPF UBNC ABZPY AP
Aboitiz Power Corp. (AboitizPower) has launched a 100-kilowatt solar rooftop installation, marking its foray into the small-scale market segment that also further expands its diverse Cleanergy brand.
ABZPF ABZPY AP
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
as of ET